Maridebart cafraglutide — compound monograph
GIP receptor antagonist and GLP-1 receptor agonist conjugate (antibody–peptide). Phase 3. The Institute assesses 2 outcomes for this compound and grades the strongest at low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Maridebart cafraglutide
- Compound class
- GIP receptor antagonist and GLP-1 receptor agonist conjugate (antibody–peptide)
- Assessment series
- Incretin receptor agonists
- Synonyms and codes
- AMG 133 · MariTide · maridebart cafraglutide (INN)
- Route as evaluated
- Subcutaneous, monthly or less frequently
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- not assigned in public records
- Molecular formula
- not applicable (antibody conjugate)
- Average mass
- ≈150,000 Da (monoclonal antibody scaffold with conjugated peptides)
- Monoisotopic mass
- not applicable
- ATC classification
- not assigned
§1.3Sequence and structural notes
This compound is pharmacologically the mirror image of tirzepatide at the GIP receptor: it antagonises rather than agonises GIPR while agonising GLP-1R. That two opposite GIP strategies both produce weight loss is one of the more striking unresolved questions in incretin pharmacology, and the Institute treats it as such rather than adopting either mechanistic account.
§1.4Assessment status
The Institute assesses Maridebart cafraglutide across 2 indications and grades the strongest of them at low certainty. In confirmatory clinical development; no marketing authorisation.
Table 1. Assessed outcomes for Maridebart cafraglutide, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Obesity and overweight in adults | −16.2 % body weight at 52 weeks at the highest dose in phase 2 versus −2.5 % with placebo | Low | 2 |
| Type 2 diabetes mellitus | −2.2 % HbA1c reported at 52 weeks in phase 2 | Low | 1 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.